Efficacy and Safety of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease Patients (EASE LID Study)

Trial Profile

Efficacy and Safety of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease Patients (EASE LID Study)

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Amantadine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Registrational; Therapeutic Use
  • Acronyms EASE LID
  • Sponsors Adamas Pharmaceuticals
  • Most Recent Events

    • 12 Jun 2017 According to an Adamas Pharmaceuticals media release, results from this trial were published online in JAMA Neurology.
    • 09 May 2017 According to an Adamas Pharmaceuticals media release, data from this trial presented at the Academy of Managed Care Pharmacys (AMCP) 2017 Annual Meeting.
    • 28 Apr 2017 Results of a pooled analysis from EASE LID and EASE LID 3 studies assessing the secondary outcome of ON time without troublesome dyskinesia and OFF time, presented at the 69th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top